A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

被引：0

作者：

Jakubowiak, Andrzej J.

Offidani, Massimo

Pegourie, Brigitte

De La Rubia, Javier

Garderet, Laurent

Laribi, Kamel

Bosi, Alberto

Marasca, Roberto

Laubach, Jacob

Mohrbacher, Ann

Carella, Angelo Michele

Singhal, Anil K.

Tsao, Claire

Lynch, Mark John

Bleickardt, Eric W.

Jou, Ying-Ming

Palumbo, Antonio

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Azienda Osped Univ Osped Riuniti Ancona, Ancona, Italy

[3] CHU Grenoble, Hop Albert Michallon, F-38043 Grenoble, France

[4] HUP La Fe, Valencia, Spain

[5] Hop St Antoine, F-75571 Paris, France

[6] Ctr Hosp, Le Mans, France

[7] Azienda Osped Univ Careggi, Florence, Italy

[8] Azienda Osped Univ, Policlin Modena, Modena, Italy

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[11] IRCCS San Martino IST, Genoa, Italy

[12] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA

[13] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[14] Osped Molinette, AOU San Giovanni Battista Torino, Turin, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8573

引用

页数：1